Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395499 · ClinicalTrials.gov registry record
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva
A clinical trial of Patients Already Taking Risperidone for Clinical Indications, sponsored by Ohio State University.
- Completed
- Registry status
- 19
- Enrollment target
- 2
- Study locations
NCT00395499: Completed study of Patients Already Taking Risperidone for Clinical Indications, sponsored by Ohio State University.
NCT00395499 is a study of Patients Already Taking Risperidone for Clinical Indications that has completed, run by Ohio State University. The registered enrollment target is 19 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00395499, a study of Patients Already Taking Risperidone for Clinical Indications, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3) compare the rate of decline in concentration of RIS and 9-OH-RIS in saliva and plasma by measurements at timed intervals during a single dosing interval.
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (2)
Ohio
- General Clinical Research Center - Columbus
- The Nisonger Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2001-05 |
| Est. Completion | 2003-04 |
What the finished NCT00395499 record still lists
NCT00395499 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 1 condition, with Patients Already Taking Risperidone for Clinical Indications appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT00395499 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00395499 about?
NCT00395499 is a clinical study titled "Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva". The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3) compare the rate of decline in concentration of RIS and 9-OH-RIS in sa...
What is the current status of trial NCT00395499?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2001-05. Estimated completion is 2003-04.
What conditions does trial NCT00395499 study?
This clinical trial studies the following conditions: Patients Already Taking Risperidone for Clinical Indications.
What interventions are being tested in trial NCT00395499?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00395499?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00395499 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia